>
Fa   |   Ar   |   En
   Present and future of EGFR inhibitors for head and neck squamous cell cancer  
   
نویسنده baba y. ,fujii m. ,tokumaru y. ,kato y.
منبع journal of oncology - 2012 - دوره : 2012 - شماره : 0
چکیده    Although egfr is expressed at high levels in head and neck squamous cell carcinomas (hnsccs) and mutations are extremely rare,monotherapy with egfr inhibitors has shown limited success. the pi3kinase/akt pathway is responsible for cellular survival,and inhibition of phosphatidylinositol (pi) synthesis has antiproliferative,anti-invasive,and antiangiogenesis effects on hnscc. molecular crosstalk has been observed between egfr and igf1r signaling through the pi3kinase/akt pathway in hnscc,as has molecular crosstalk between the nfκb and stat3 signaling pathways. therefore,the combination of an egfr antagonist with an agent that inhibits the activation of both akt and nfκb may overcome resistance to egfr antagonists in hnscc. copyright 2012 yuh baba et al.
آدرس department of otorhinolaryngology and head and neck surgery,ohtawara red cross hospital,2-7-3,sumiyoshi-cho,ohtawara city,tochigi 324-8686,japan,national institute of sensory organs,national tokyo medical center,2-5-1,higashigaoka,meguro,tokyo 152-8902,japan,department of oral function and molecular biology,ohu university,31-1,mitsumido,tomita-machi,koriyama city, Japan, national institute of sensory organs,national tokyo medical center,2-5-1,higashigaoka,meguro, Japan, national institute of sensory organs,national tokyo medical center,2-5-1,higashigaoka,meguro, Japan, department of oral function and molecular biology,ohu university,31-1,mitsumido,tomita-machi,koriyama city, Japan
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved